Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Cimzia | certolizumab pegol | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cimzia | Certolizumab pegol | Ankylosing spondylitis | List with criteria/condition | Complete | ||
| Cimzia | Certolizumab pegol | Arthritis, psoriatic | List with criteria/condition | Complete | ||
| Cimzia | Certolizumab pegol | Arthritis, rheumatoid | Do not list | Complete | ||
| Cibinqo | abrocitinib | Atopic dermatitis, moderate to severe | Reimburse with clinical criteria and/or conditions | Complete | ||
| Champix | Varenicline tartrate | Smoking-cessation | List with clinical criteria and/or conditions | Complete | ||
| Cerdelga | Eliglustat | Gaucher disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Celsentri | Maraviroc | HIV | Withdrawn | |||
| Celsentri | Maraviroc | HIV | List with clinical criteria and/or conditions | Complete | ||
| Celsentri | Maraviroc | HIV infection | Do not list | Complete |
Last Updated : April 27, 2024